Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy Subjects

Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials

(2022) Emmanuel Mignot et al.   LANCET NEUROLOGY

Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous Biomarkers

(2022) Manoli Vourvahis et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial

(2022) Ingo Fietze et al.   DRUGS & AGING

Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist

(2022) Andreas Krause et al.   CPT-Pharmacometrics & Systems Pharmacology

Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder

(2022) Dieter Kunz et al.   CNS DRUGS

Novel inhibitors of breast cancer resistance protein (BCRP, ABCG2) among marketed drugs

(2022) Feng Deng et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Effect of the novel dual orexin receptor antagonist daridorexant on night‐time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease

(2021) Marie‐Laure Boof et al.   JOURNAL OF SLEEP RESEARCH

Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment

(2021) Benjamin Berger et al.   CTS-Clinical and Translational Science

Comparative Hepatic and Intestinal Efflux Transport of Statins

(2021) Feng Deng et al.   DRUG METABOLISM AND DISPOSITION

Quantification of CYP3A and Drug Transporters Activity in Healthy Young, Healthy Elderly and Chronic Kidney Disease Elderly Patients by a Microdose Cocktail Approach

(2021) Punyabhorn Rattanacheeworn et al.   Frontiers in Pharmacology

Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder

(2020) Gary Zammit et al.   NEUROLOGY

The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin

(2020) Isabelle Zenklusen et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment

(2020) Daniel A. Tatosian et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P‐gp and BCRP

(2020) Ying C. Ou et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Investigating the Metabolism of ACT-541468, Utilizing a Microtracer and Accelerator Mass Spectrometry in The First-in-Humans Trial

(2019) Clemens Muehlan et al.   CURRENT DRUG METABOLISM

Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration

(2019) Clemens Muehlan et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration

(2019) Clemens Muehlan et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Clinically Negligible Pharmacokinetic and Pharmacodynamic Interactions Between Lanabecestat and Dabigatran Etexilate, a Prototypical P‐gp Substrate

(2019) Scott A. Monk et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability

(2019) Hans Ericsson et al.   Clinical Pharmacology in Drug Development

Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine

(2018) Justin D. Lutz et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin

(2018) Justin D. Lutz et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Accelerated Development of the Dual Orexin Receptor Antagonist ACT-541468: Integration of a Microtracer in a First-in-Human Study

(2018) Clemens Muehlan et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Age- and Genotype-Dependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphate-Glucuronosyltransferases in Human Liver

(2018) Deepak Kumar Bhatt et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters

(2018) Takayuki Katsube et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Dabigatran Etexilate and Digoxin: Comparison as Clinical Probe Substrates for Evaluation of P-gp Inhibition

(2018) Xiaoyan Chu et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Basic coagulation tests as surrogates of dabigatran levels in a pre-operative setting: Analysis of five activated partial thromboplastin time reagents and thrombin time

(2018) Catherine Dubé et al.   THROMBOSIS RESEARCH

Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A

(2016) T Prueksaritanont et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacogenetics of dabigatran etexilate interindividual variability

(2016) Claudia Dimatteo et al.   THROMBOSIS RESEARCH

Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies

(2016) P. Martin et al.   Drugs in research & development

Diluted thrombin time reliably measures low to intermediate plasma dabigatran concentrations

(2016) Mojca Božič-Mijovski et al.   ANNALS OF CLINICAL BIOCHEMISTRY

Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States

(2015) Bruce K. Birmingham et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update

(2014) Qingcheng Mao et al.   AAPS Journal

What do drug transporters really do?

(2014) Sanjay K. Nigam   NATURE REVIEWS DRUG DISCOVERY

Plasma-Diluted Thrombin Time to Measure Dabigatran Concentrations During Dabigatran Etexilate Therapy

(2012) Scott T. Avecilla et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin

(2012) Sebastian Härtter et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

Evaluation and performance characteristics of the coagulation system: ACL TOP analyzer - HemosIL reagents

(2009) M. MILOS et al.   International Journal of Laboratory Hematology